

GROUP VII VIRUSES

- ◆ **Hepatitis B is the only Group VII virus that has been reported to be effectively purified in an iodixanol gradient, prepared from OptiPrep™.**
- ◆ **Publications are listed alphabetically by first author and, where necessary, references are further divided according to research topic.**
- ◆ **Multiple entries from the same first author are listed chronologically.**
- ◆ **For a detailed methodology of Group VII viruses see OptiPrep™ Application Sheet V36. V06 is a methodological review of OptiPrep™ technology.**

Hepatitis B virus

- Abdul, F.**, Ndeboko, B., Buronfosse, T., Zoulim, F., Kann, M., Nielsen, P.E. and Cova, L. (2012) *Potent inhibition of late stages of hepadnavirus replication by a modified cell penetrating peptide* PLoS One, **7**: e48721
- Aillot, L.**, Bonnin, M., Ait-Goughoulte, M., Bendriss-Vermare, N., Maadadi, S., Dimier, L., Subic, M., Scholtes, C., Najera, I. et al (2018) *Interaction between toll-like receptor 9-CpG oligodeoxynucleotides and hepatitis B virus virions leads to entry inhibition in hepatocytes and reduction of alpha interferon production by plasmacytoid dendritic cells* Antimicrob. Agents Chemother., **62**: e01741-17
- Bardens, A.**, Döring, T., Stieler, J. and Prange, R. (2011) *Alix regulates egress of hepatitis B virus naked capsid particles in an ESCRT-independent manner* Cell. Microbiol., **13**, 602–619
- Burwitz, B.J.**, Wettenge, L.M., Mück-Häus, M.A., Ringelhan, M., Ko, C., Festag, M.M., Hammond, K.B., Northrup, M. et al (2017) *Hepatocytic expression of human sodium taurocholate co-transporting polypeptide enables hepatitis B virus infection of macaques* Nat. Comm., **8**: 2146
- Faure-Dupuy, S.**, Delphin, M., Ailot, L., Dimier, L..... Heikenwalder, M., Durantel, D., Lucifora, J. et al (2019) *Hepatitis B virus-included modulation of liver macrophage function promotes hepatocyte infection* J. Hepatol., **71**, 1086-1098
- Feng, X.**, Liu, H., Chu, X., Sun, P., Huang, W., Liu, C., Yang, X., Sun, W., Bai, H. and Ma, Y. (2019) *Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer* Acta Biomaterialia, **100**, 316–325
- Hallez, C.**, Li, X., Suspène, R., Thiers, V., Bouzidi, M.S., Dorobantu, C.M., Lucansky, V., Wain-Hobson, S., Gaudin, R. and Vartanian, J-P., (2019) *Hypoxia-induced human deoxyribonuclease I is a cellular restriction factor of hepatitis B virus* Nat. Microbiol., **1196**, 1196–1207
- Inoue, J.** et al (2017) *Rab5B determines HBV release pathways by promoting transport of LHBs from ER to MVB* Hepatology, **66** (Suppl.) Abstr. #1491
- Kim, S.**, Lee, J. and Ryu, W-S. (2009) *Four conserved cysteine residues of the hepatitis B virus polymerase are critical for RNA pregenome encapsidation* J. Virol., **83**, 8032-8040
- Komatsu, H.**, Inui, A., Murano, T., Tsunoda, T., Sogo, T. 2 and Fujisawa, T. (2015) *Lack of infectivity of HBV in feces from patients with chronic hepatitis B virus infection, and infection using chimeric mice* BMC Res. Notes, **8**: 366
- Kratochwil, N.A.**, Triyatni, M., Mueller, M.B., Klammers, F., Leonard, B., Turley, D., Schmalzer, J., Ekiciler, A., Molitor, B. et al (2018) *Simultaneous assessment of clearance, metabolism, induction, and drug-drug interaction potential using a long-term in vitro liver model for a novel hepatitis B virus inhibitor* J. Pharmacol. Exp. Ther., **365**, 237–248
- Li, F.**, Cheng, L., Murphy, C.M., Reszka-Blanco, N.J., Wu, Y., Chi, L., Hu, J. and Su, L. (2016) *Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs* Sci. Rep., **6**: 36483
- Lam, A.M.**, Ren, S., Espiritu, C., Kelly, M., Lau, V., Zheng, L., Hartman, G.D., Flores, O.A. and Klumpp, K. (2017) *Hepatitis B virus capsid assembly modulators, but not nucleoside analogs, inhibit the production of extracellular pregenomic RNA and spliced RNA variants* Antimicrob. Agents Chemother., **61**: e00680-17
- Maepa, M.B.**, Ely, A., Grayson, W. and Arbuthnot, P. (2017) *Sustained inhibition of HBV replication in vivo after systemic injection of AAVs encoding artificial antiviral primary microRNAs* Mol. Ther. Nucleic Acids, **7**, 190-199

- Montpellier, C.** et al (2018) *Hepatitis E virus lifecycle and identification of 3 forms of the ORF2 capsid protein* J. Hepatol., **68** (Suppl. 1) Abstr. SAT-386
- Scott, T.**, Moyo, B., Nicholson, S., Maepa, M.B., Watashi, K., Ely, A., Weinberg, M.S. and Arbuthnot, P. (2017) *ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells* Sci. Rep., **7**: 7401
- Verrier, E.R.**, Colpitts, C.C., Bach, C., Heydmann, L., Weiss, A., Renaud, M., Durand, S.C., Habersetzer, F., Durante, D. et al (2016) *A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses* Hepatology, **36**, 35-48
- Wang, H.**, Kim, S. and Ryu, W-S. (2009) *DDX3 DEAD-box RNA helicase inhibits hepatitis B virus reverse transcription by incorporation into nucleocapsids* J. Virol., **83**, 5815–5824
- Yao, Y.**, Yang, B., Chen, Y., Wang, H., Hu, X., Zhou, Y., Gao, X., Lu, M., Niu, J. et al (2019) *RNA-binding motif protein 24 (RBM24) is involved in pregenomic RNA packaging by mediating interaction between hepatitis B virus polymerase and the epsilon element* J. Virol., **93**, e02161-18
- Zannetti, C.**, Roblot, G., Charrier, E., Ainouze, M., Tout, I., Briat, F., Isorce, N., Faure-Dupuy, S., Michelet, M. et al (2016) *Characterization of the inflammasome in human Kupffer cells in response to synthetic agonists and pathogens* J. Immunol., **197**, 356-367

OptiPrep™ Reference List RV07: 2nd edition, January 2020